Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
OlympiAD Final Overall Survival and Tolerability Results: Olaparib Versus Chemotherapy Treatment of Physician’s Choice in Patients With a Germline BRCA Mutation and HER2-Negative Metastatic Breast CancerAnn. Oncol 2019 Jan 23;[EPub Ahead of Print], ME Robson, N Tung, P Conte, SA Im, E Senkus, B Xu, N Masuda, S Delaloge, W Li, A Armstrong, W Wu, C Goessl, S Runswick, SM Domchek
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.